Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD

NCT Number	NCT04925375
Lead Sponsor	Children's Hospital Medical Center, Cincinnati Collaborators: Bristol-Myers Squibb
Conditions	Interstitial Lung Disease, Common Variable Immunodeficiency
Enrollment	38 participants
Start Date	2021-07-14
Primary Completion	2028-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-22